Keywords: Proteon Therapeutics, Funding, Novartis acquisition option, Kidney disease, PRT-201

Proteon Thera gets new funding of $15 million, ahead of Novartis acquisition option

Article | 15 August 2011

Print This

US privately-held biopharmaceutical firm Proteon Therapeutics, the subject of a takeover option by Swiss drug major Novartis (NOVN: VX) has ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in